Traditional approaches to prevention of the complications of type 2 diabetes (T2D) and
obesity have focused on reduction of blood glucose and body weight. The development of …

The burden of chronic kidney disease (CKD) and its risk factors are projected to rise in
parallel with the rapidly ageing global population. By 2050, the prevalence of CKD category …

ABSTRACT In the EMPA-KIDNEY (The Study of Heart and Kidney Protection With
Empagliflozin) trial, empagliflozin reduced cardiorenal outcomes by 28%(hazard ratio 0.72; …

Tirzepatide is a twincretin recently approved to improve glycemic control in type 2 diabetes
mellitus (T2DM). More specifically, tirzepatide is an agonist of both the glucose-dependent …

Importance Type 2 diabetes (T2D) is the leading cause of kidney disease in the US. It is not
known whether glucose-lowering medications differentially affect kidney function. Objective …

OBJECTIVE To develop a risk assessment tool to identify patients with type 2 diabetes (T2D)
at higher risk for kidney disease progression and who might benefit more from sodium …

T2D is a well-established risk factor for development and progression of CKD. KDIGO
recommends categorization of risk by likelihood of progression to ESKD. Compared to …

Background Despite the overall improvement in care, people with type 2 diabetes (T2D)
experience an excess risk of end-stage kidney disease. We evaluated the long-term …

Background Contemporary guidelines recommend the use of sodium-glucose cotransporter
2 inhibitors (SGLT2is) independently of glycemic control in patients with type 2 diabetes and …

Maintaining a balance between the supply and demand of oxygen is vital for proper organ
function. Most types of acute kidney injury (AKI) are characterized by hypoxia, a state where …